Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8WW27

UPID:
ABEC4_HUMAN

ALTERNATIVE NAMES:
Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 4

ALTERNATIVE UPACC:
Q8WW27; Q8N7F6

BACKGROUND:
APOBEC-4, with its alternative name Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 4, is a putative C to U editing enzyme. The enzyme's physiological targets and editing capabilities are yet to be discovered, positioning it as a promising area for research within molecular biology and genetics.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of APOBEC-4 holds the promise of unveiling novel therapeutic avenues. Given its potential role in RNA editing, APOBEC-4 could be instrumental in developing innovative treatments for a range of diseases by modulating gene expression.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.